Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.

Mayall, Steve; Kahlon, Randip; Al-Dakkak, Imad; Shen, Sophie W

Mayall, Steve; Kahlon, Randip; Al-Dakkak, Imad; Shen, Sophie W.

Afiliación

Mayall S; Development Consulting, Pope Woodhead and Associates Ltd (now part of Axian Consulting Ltd, Cambridge, UK), St Ives, Cambridgeshire, UK. s_mayall@outlook.com.
Kahlon R; Worldwide Patient Safety, Bristol Myers Squibb, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK.
Al-Dakkak I; Development Consulting, Pope Woodhead and Associates Ltd (now part of Axian Consulting Ltd, Cambridge, UK), St Ives, Cambridgeshire, UK.
Shen SW; Worldwide Patient Safety, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ, 08540, USA.

Pharmaceut Med ; 35(2): 123-135, 2021 03.

Article en En | MEDLINE | ID: mdl-33660230

Asunto(s)

Personal de Salud; Estudios Transversales; Europa (Continente); Humanos; Pirazoles; Piridonas; Encuestas y Cuestionarios

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Personal de Salud Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Pharmaceut Med Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google